机构:[1]Department of Dermatology, The First People's Hospital of Foshan, Foshan, China.[2]Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China.[3]Department of Burn and Plastic Surgery, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, China.
This study was supported by the National Natural Science
Foundation of China (82002913), Guangdong Basic and
Applied Basic Research Foundation (2021A1515011453,
2022A1515012160, 2021B1515120036, and 2022A1515012245),
the Medical Scientific Research Foundation of Guangdong
Province (A2022293), Foshan 14th - fifth high-level key specialty construction project, Yunnan Fundamental Research
Projects (grant NO. 202001AT070145, 202101AT070288).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类|4 区医学
小类|4 区外科
最新[2023]版:
大类|4 区医学
小类|4 区外科
第一作者:
第一作者机构:[1]Department of Dermatology, The First People's Hospital of Foshan, Foshan, China.
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Zhou Sitong,Han Yuanyuan,Yang Ronghua,et al.TIMM13 as a prognostic biomarker and associated with immune infiltration in skin cutaneous melanoma (SKCM)[J].Frontiers in surgery.2022,9:990749.doi:10.3389/fsurg.2022.990749.
APA:
Zhou Sitong,Han Yuanyuan,Yang Ronghua,Pi Xiaobing&Li Jiehua.(2022).TIMM13 as a prognostic biomarker and associated with immune infiltration in skin cutaneous melanoma (SKCM).Frontiers in surgery,9,
MLA:
Zhou Sitong,et al."TIMM13 as a prognostic biomarker and associated with immune infiltration in skin cutaneous melanoma (SKCM)".Frontiers in surgery 9.(2022):990749